www.tickerreport.com ·
pfizer nysepfe stock price down 1 7 heres why
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPfizer's stock decline reflects investor concerns over declining COVID-related sales and patent expirations, partially offset by pipeline progress (Hympavzi label expansion). The impact is company-specific, with no direct commodity or supply chain scarcity. Sector: PHARMA_BIOTECH. Channel: revenue/margin pressure from patent cliffs and COVID revenue fade.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Pfizer stock down 1.7% to $25.3090 on May 17, 2026.
- Volume 36,875,136 shares, down 13% from average.
- Label expansion for hemophilia therapy Hympavzi announced.
- Q1 2026 earnings positive but COVID sales declining.
- Quarterly dividend $0.43 per share declared.
Pfizer faces mid-term revenue decline of 2-4% due to patent expirations and COVID sales fade over 2-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
transcript valneva q1 2026 earnings 155143868
finance.yahoo.com
logicmark inc q1 2026 earnings 212238423
nwaonline.com
warsh okd by us senate as fed leader
livemint.com